C4 Therapeutics (CCCC) Enterprise Value (2019 - 2025)
Historic Enterprise Value for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$191.9 million.
- C4 Therapeutics' Enterprise Value rose 2494.01% to -$191.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$191.9 million, marking a year-over-year increase of 2494.01%. This contributed to the annual value of -$244.9 million for FY2024, which is 345.99% up from last year.
- As of Q3 2025, C4 Therapeutics' Enterprise Value stood at -$191.9 million, which was up 2494.01% from -$214.6 million recorded in Q2 2025.
- C4 Therapeutics' 5-year Enterprise Value high stood at -$191.9 million for Q3 2025, and its period low was -$465.9 million during Q2 2021.
- For the 5-year period, C4 Therapeutics' Enterprise Value averaged around -$280.6 million, with its median value being -$267.3 million (2023).
- Data for C4 Therapeutics' Enterprise Value shows a peak YoY increase of 4477.18% (in 2021) and a maximum YoY decrease of 33279.36% (in 2021) over the last 5 years.
- Over the past 5 years, C4 Therapeutics' Enterprise Value (Quarter) stood at -$309.3 million in 2021, then grew by 10.71% to -$276.2 million in 2022, then increased by 8.14% to -$253.7 million in 2023, then grew by 3.46% to -$244.9 million in 2024, then grew by 21.65% to -$191.9 million in 2025.
- Its last three reported values are -$191.9 million in Q3 2025, -$214.6 million for Q2 2025, and -$215.1 million during Q1 2025.